Alector ALEC 深 沪
等待开盘 09-23 09:30:00 美东时间
3.18
+0.150
+4.95%
华盛通- 最 高3.255
- 今 开3.02
- 成交量 109.94万股
- 最 低 2.95
- 昨 收 3.03
- 总市值 3.21亿
- 52周最高 6.14
- 市盈率 静 --
- 换手率 1.09%
- 52周最低 0.87
- 委 比 11.33%
- 总股本 1.01亿
- 历史最高 43.32
- 量 比 0.94
- 振 幅 10.07%
- 历史最低 0.87
- 每 手 1
- 风险率 1.35%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Alector to Host Virtual Research and Development Event Highlighting PGRN Franchise and Brain Carrier Programs
Alector will host a virtual event on September 22, 2025, to discuss its PGRN franchise, including latozinemab (Phase 3 for GRN-related frontotemporal dementia) and AL101 (Phase 2 for early Alzheimer’s disease), as well as progress in its Alector Brain Carrier (ABC)-enabled programs. The event will feature preclinical data on new candidates for Alzheimer’s and Parkinson’s diseases, and updates on ABC-enabled siRNA programs. ABC aims to enhance the...
09-16 12:00
Top 4 Biotech Stocks Set For A Breakout: Momentum Scores Surge
Several biotech stocks are showing renewed strength over the past week, with their Momentum scores soaring in Benzinga's Edge Stock Rankings.
09-08 17:59
Alector to Participate in Upcoming Healthcare Conferences
Alector, Inc. announced that its management will participate in three upcoming investor conferences in New York: the Cantor Global Healthcare Conference 2025 on September 4, the Morgan Stanley 23rd Annual Global Healthcare Conference on September 8, and the H.C. Wainwright 27th Annual Global Investment Conference on September 9. Webcasts of the presentations will be available on Alector’s website, with replays accessible for 90 days. Alector focu...
08-28 12:00
Alector Raises FY2025 Sales Guidance from $5.000M-$15.000M to $13.000M-$18.000M vs $12.114M Est
Alector (NASDAQ:ALEC) raises FY2025 sales outlook from $5.000 million-$15.000 million to $13.000 million-$18.000 million vs $12.114 million estimate.
08-08 04:48
Here are the major earnings after the close Thursday
Major earnings expected after the bell on Thursday include: Block (XYZ) Gilead Sciences (GILD) Twilio (TWLO) The Trade Desk (TTD) Main Street Capital Corporation (MAIN) Other earnings slated for rele...
08-07 22:00
Alector Reports Second Quarter 2025 Financial Results and Provides Business Update
Alector reported Q2 2025 financial results and updates on its pipeline, including the pivotal INFRONT-3 Phase 3 trial of latozinemab for FTD-GRN, expected to report top-line data by mid-Q4 2025. The Phase 2 PROGRESS-AD trial of AL101 in early Alzheimer's disease is ongoing, with completion expected in 2026. The company also highlighted progress in its Brain Carrier programs, including anti-amyloid beta, GCase enzyme replacement therapy, and anti-...
08-07 20:05
Earnings Scheduled For August 7, 2025
Companies Reporting Before The Bell • GoHealth (NASDAQ:GOCO) is estimated to re...
08-07 16:33
Alector to Host Second Quarter and Mid-Year 2025 Earnings Conference Call
<p>Alector, a clinical-stage biotech company focused on neurodegenerative diseases, announced a conference call on August 7, 2025, at 4:30 p.m. ET, to discuss Q2 2025 results and mid-year updates. A press release will be issued prior to the call, and a webcast will be available under the investor relations section of Alector’s website. Participants can register online to join by phone. Ryan Darby, MD, will discuss the unmet need in frontotemporal...
07-31 20:05
Alector upgraded at Mizuho on high risk/higher-reward
Alector (NASDAQ:ALEC) was surging after Mizuho Securities upgraded the biotechnology stock, citing "high risk/higher-reward bet". Shares were +9.09% during morning trade to $1.92. "Investing in the ne...
07-28 22:46
Mizuho Upgrades Alector to Outperform, Raises Price Target to $3.5
Mizuho analyst Graig Suvannavejh upgrades Alector (NASDAQ:ALEC) from Neutral to Outperform and raises the price target from $2.5 to $3.5.
07-28 19:08
